Morepen Laboratories (NSE:MOREPENLAB) Notes Receivable: ₹0 Mil (As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
74 GF Score
Price ₹53.16
GF Value ₹50.02
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Morepen Laboratories Notes Receivable?

Morepen Laboratories NSE:MOREPENLAB +2.00% 74 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹50.02 (Fairly Valued). The stock has 6 warning signs investors should review.

Morepen Laboratories's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Morepen Laboratories Notes Receivable Related Terms

Morepen Laboratories Notes Receivable Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Notes Receivable Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MOREPENLAB
74GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Notes Receivable too high?
Morepen Laboratories' current Notes Receivable is ₹0 Mil. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Notes Receivable compare to ZTS?
Morepen Laboratories' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹50.02, compared to a current price of ₹53.16 — trading 6.3% above its estimated fair value. The current Notes Receivable is ₹0 Mil. Morepen Laboratories' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹53.16 is trading 6.3% above its estimated GF Value™ of ₹50.02. GuruFocus considers Morepen Laboratories to be Fairly Valued.

Key valuation signals for NSE:MOREPENLAB:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹50.02 vs. price of ₹53.16 (6.3% above fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score

Get the complete analysis for NSE:MOREPENLAB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹53.16
Price
₹50.02
GF Value